New lung cancer drug gets US approval as first-line treatment

13 Jul 2015

The U.S. Food and Drug Administration (FDA) approved AstraZeneca's drug, Iressa, as a first-line treatment for a common form of lung cancer.

The FDA said the approval was based on results from a trial of 106 patients with previously untreated non-small cell lung cancer.


Valuable treatment for lung cancer patients

The drug was previously approved for use only in patients who did not respond to chemotherapy.

Drugs like Iressa and Roche's Tarceva have been on the market for several years and provide a valuable treatment option for some lung cancer patients with a certain genetic mutation.

Source: Reuters
No Comment